European Rare Diseases Research Alliance (ERDERA): Joint Transnational Call (JTC) 2025 "Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”

European Rare Diseases Research Alliance (ERDERA) aims to to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium. 

The topic of ERDERA Joint Transnational Call (JTC) 2025 is: "Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”

1. development of novel therapies in a preclinical setting through cell, organoid and animal model studies, molecule screening or use of in silico or artificial intelligence models
2. development of predictive and pharmacodynamics biomarkers correlated to the efficiency of the therapy in a preclinical setting that could serve as surrogate endpoints
3. replication of pre-clinical studies in an independent lab to increase validity of exploratory findings
4. pre-clinical proof of concept studies for evidence of pharmacological activity in vitro and in vivo, pharmaco-kinetics and pharmaco-dynamics of the drug and first toxicology and safety data
5. studies to support readiness for initiating clinical trial authorization conforming to regulatory requirements

Full proposal documentation to be published on Dec. 10th, 2024.

A consortium of 4-6 partners from a minimum of 4 countries is required. 

Funding: €140,000 total for the Israeli partner +€20,000 for coordination

Duration: 3 years

Research Authority due date: 6.2.25

Pre proposal (required) due date: 13.2.25